Point Biopharma finds big licensing partner, but stock falls after Q3 loss widens
It was supposed to be a “good-news” day for Indianapolis-based biotech Point Biopharma Global Inc. Instead, the company saw its stock get battered Monday, losing as much as 38% of its value, after it released a pair of announcements.